These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34105810)

  • 1. New drugs and pharmacological interactions in real life.
    Stathis A
    Hematol Oncol; 2021 Jun; 39 Suppl 1():78-82. PubMed ID: 34105810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hematologic Malignancies/Pediatric Malignancies. Roles of Drugs Approved as New Agents and as Additional Indications for Relapse or Refractory Hematologic Malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2016 May; 43(5):528-9. PubMed ID: 27344679
    [No Abstract]   [Full Text] [Related]  

  • 3. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
    Cosenza M; Pozzi S
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30096875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel and Expanded Oncology Drug Approvals of 2016-PART 2: New Options in the Management of Hematologic Malignancies.
    Knepper TC; Saller J; Walko CM
    Oncology (Williston Park); 2017 Feb; 31(2):138-46. PubMed ID: 28205194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antineoplastic agents and biologic response modifiers in oncologic hematology].
    Cabrera Marín JR; Briz del Blanco M
    Rev Clin Esp; 1999 Apr; 199 Suppl 1():3-13. PubMed ID: 10422445
    [No Abstract]   [Full Text] [Related]  

  • 6. Duvelisib, a new PI3K inhibitor for lymphoid malignancies.
    Lamanna N
    Clin Adv Hematol Oncol; 2020 Oct; 18(10):606-608. PubMed ID: 33201865
    [No Abstract]   [Full Text] [Related]  

  • 7. [Current issues concerning drug development for pediatric hematologic malignancies].
    Sekimizu M
    Rinsho Ketsueki; 2016 Jun; 57(6):693-700. PubMed ID: 27384847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies.
    Gafter-Gvili A; Tibau A; Raanani P; Shepshelovich D
    Acta Haematol; 2020; 143(1):73-77. PubMed ID: 31167178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy in haematological malignancies.
    Hamilton A; Gallipoli P; Nicholson E; Holyoake TL
    J Pathol; 2010 Mar; 220(4):404-18. PubMed ID: 20041451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procarbazine in haematology: an old drug with a new life?
    Massoud M; Armand JP; Ribrag V
    Eur J Cancer; 2004 Sep; 40(13):1924-7. PubMed ID: 15315798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies.
    Kater AP; Tonino SH; Spiering M; Chamuleau MED; Liu R; Adewoye AH; Gao J; Dreiling L; Xin Y; Doorduijn JK; Kersten MJ;
    Blood Cancer J; 2018 Feb; 8(2):16. PubMed ID: 29434192
    [No Abstract]   [Full Text] [Related]  

  • 12. Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies.
    Robak T; Korycka A; Robak E
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):23-38. PubMed ID: 18221024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study with a new alkylating agent (PTT-119) in lymphoid malignancies.
    Tura S; Mazza P; Gherlinzoni F; Zinzani PL; Poletti G; Visani G; Lemoli RM; Bandini G; Cavo M; Galieni P
    Haematologica; 1988; 73(6):503-8. PubMed ID: 3148513
    [No Abstract]   [Full Text] [Related]  

  • 14. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.
    Bassan R; Chiodini B; Zucchetti M; Lerede T; Cornelli PE; Cortelazzo S; Barbui T
    Haematologica; 1998 Jan; 83(1):27-33. PubMed ID: 9542320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptotic events induced by a natural plastoquinone from the marine alga Desmarestia menziesii in lymphoid neoplasms.
    Santos-Pirath IM; Walter LO; Maioral MF; Philippus AC; Zatelli GA; Horta PA; Colepicolo P; Falkenberg MB; Santos-Silva MC
    Exp Hematol; 2020 Jun; 86():67-77.e2. PubMed ID: 32422231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balancing patient value and payer cost in hematologic malignancies: can it be done?
    Allen PB; Flowers CR
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):123-126. PubMed ID: 29486601
    [No Abstract]   [Full Text] [Related]  

  • 17. Idelalisib approved for trio of blood cancers.
    Cancer Discov; 2014 Oct; 4(10):OF6. PubMed ID: 25274697
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
    Fancher KM; Pappacena JJ
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):507-515. PubMed ID: 32940733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate in the treatment of hematologic malignancies.
    Piccaluga PP; Rondoni M; Paolini S; Rosti G; Martinelli G; Baccarani M
    Expert Opin Biol Ther; 2007 Oct; 7(10):1597-611. PubMed ID: 17916051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice.
    Argnani L; Broccoli A; Pellegrini C; Casadei B; Zinzani PL
    Hematol Oncol; 2017 Dec; 35(4):918-920. PubMed ID: 27862141
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.